ClinConnect ClinConnect Logo
Search / Trial NCT05134792

Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients

Launched by CAIRO UNIVERSITY · Nov 24, 2021

Trial Information

Current as of May 06, 2025

Completed

Keywords

ClinConnect Summary

After randomization, Treatment and control groups will receive Parkland formula (4 ml/kg per percent total burn surface area; (TBSA), counting moderate (partial thickness) and severe (full thickness) burn area only) using Ringer's lactate solution (half of the fluid will be given over the first eight hours and the remaining half will be given over the next 16 hours), plus normal 24-hour maintenance fluid requirements using glucose solution.

When initiating Parkland, treatment group (Group A) will receive intravenous immunoglobulin IVIG (LIV-GAMMA "S/D treated Human Immunoglobulin" 2.5 gram...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All burn patients 1 to 5 years old with 10% or greater burn area of TBSA .
  • Exclusion Criteria:
  • Patients with septic shock (evidence of infection and inotropes) .
  • Burns more than 48 hours duration.

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Trial Officials

Hanan Mostafa

Principal Investigator

lecturer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials